Study: Daiichi Sankyo's anticoagulant outperforms standard treatment

Data on more than 8,000 patients with venous thromboembolism showed that those who received Daiichi Sankyo's anticoagulant drug edoxaban had fewer cases of bleeding than those who received warfarin. The drug also appeared to be safer than standard treatment and works well for patients with more severe conditions, researchers reported in the New England Journal of Medicine.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC